The CIIE continues to witness Bayer's innovative therapies expanding the boundaries of patient benefit.
Bayer's active new drugs applications for approval enabled the global innovation to reach patients in China at one of the fastest speeds globally, demonstrating how Bayer is leveraging China's increasingly efficient regulatory environment to accelerate access to global innovation for Chinese patients.
Precision diagnosis and treatment depend on advanced imaging technologies. At this year's CIIE, Bayer is also presenting its latest Radiology innovations. Gadoquatrane injection is making its China debut at this year's CIIE. Its marketing application has been accepted by China's CDE for contrast enhancement in magnetic resonance imaging (MRI) in adults and pediatric patients of all ages, including neonates. The MEDRAD Mark 7 Arterion Injection System, which received registration as a domestically manufactured medical device in April 2026, is making its first CIIE appearance following localization, highlighting Bayer's continued progress in strengthening local manufacturing and supply capabilities for advanced imaging equipment.
